GW Pharmaceuticals PLC- (NASDAQ:GWPH) is scheduled to post its quarterly earnings results before the market opens on Monday, December 4th. Analysts expect GW Pharmaceuticals PLC- to post earnings of ($1.72) per share for the quarter.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $122.95 on Friday. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $136.95. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02.

An institutional investor recently bought a new position in GW Pharmaceuticals PLC- stock. State Street Corp purchased a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,114 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. 81.85% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the company. Maxim Group cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating and set a $61.00 target price for the company. in a report on Tuesday, August 8th. Cowen restated an “outperform” rating and set a $165.00 target price on shares of GW Pharmaceuticals PLC- in a report on Monday, October 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Leerink Swann reaffirmed an “outperform” rating and issued a $160.00 price target (down previously from $162.00) on shares of GW Pharmaceuticals PLC- in a research report on Thursday, August 10th. Finally, BidaskClub lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $144.55.

ILLEGAL ACTIVITY NOTICE: “GW Pharmaceuticals PLC- (GWPH) Scheduled to Post Earnings on Monday” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/12/01/gw-pharmaceuticals-plc-gwph-scheduled-to-post-earnings-on-monday.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Earnings History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.